secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001193125-23-292799
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine reports positive updated Phase 2 BEACON data for bitopertin; PPIX drops >40%, sunlight tolerance improves
--------------------------------------------------------------------------------

- PPIX levels reduced >40% (p<0.001) from baseline; sustained and dose-dependent in 22 EPP patients.
- Time to prodrome improved >3x; proportion of days without symptoms rose to 78% vs 33% baseline.
- Mean cumulative time in light over 6 months: 222.6 hours (>3x historical control) on precedented pivotal endpoint.
- Bitopertin well-tolerated with no serious AEs; stable mean hemoglobin, no anemia events reported.
- Initial positive Phase 1b data for DISC-0974 in myelofibrosis showed hemoglobin improvements and reduced transfusions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523292799/0001193125-23-292799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523292799/d638553d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer